These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31041348)

  • 1. Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points.
    Torres A; Rank D; Melnick D; Rekeda L; Chen X; Riccobene T; Critchley IA; Lakkis HD; Taylor D; Talley AK
    Open Forum Infect Dis; 2019 Apr; 6(4):ofz149. PubMed ID: 31041348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
    Tichy E; Torres A; Bassetti M; Kongnakorn T; Di Virgilio R; Irani P; Charbonneau C
    Clin Ther; 2020 May; 42(5):802-817. PubMed ID: 32349879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients.
    Shi Y; Hu J; Liu P; Wang T; Wang H; Liu Y; Cao Q; Zuo X
    Infect Dis Ther; 2021 Dec; 10(4):2721-2734. PubMed ID: 34652713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
    Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
    Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections.
    Tan CK; Lai CC; Chao CM
    Antibiotics (Basel); 2019 Dec; 8(4):. PubMed ID: 31817727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of ceftazidime-avibactam versus meropenem in Indian patients with nosocomial pneumonia: Subset analysis from the REPROVE study.
    Sathe P; Kamat S; Adhav C
    Indian J Med Microbiol; 2021 Jul; 39(3):363-366. PubMed ID: 34045081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
    Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
    J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
    Chen Y; Huang HB; Peng JM; Weng L; Du B
    Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant
    Abu Jaber AMR; Basgut B; Hawan AA; Al Shehri AA; AlKahtani SA; Ahmed NJ; Abdi A
    Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.
    Shields RK; Horcajada JP; Kamat S; Irani PM; Tawadrous M; Welte T
    Infect Dis Ther; 2024 Jul; 13(7):1639-1664. PubMed ID: 38822167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.
    Falcone M; Viale P; Tiseo G; Pai M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
    Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.
    Xu C; Zeng F; Huang Y; Xu Q; Yang Y; Gong W; Shi C; Zhang Y
    Int J Antimicrob Agents; 2024 Jan; 63(1):107021. PubMed ID: 37890733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli.
    Chen W; Sun L; Guo L; Cao B; Liu Y; Zhao L; Lu B; Li B; Chen J; Wang C
    Ann Transl Med; 2020 Feb; 8(3):39. PubMed ID: 32154284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China.
    Shi X; Fu J; Li X; Lv Q; Wan X; Xu Q
    J Infect Public Health; 2023 Mar; 16(3):361-367. PubMed ID: 36689854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa.
    Corbella L; Boán J; San-Juan R; Fernández-Ruiz M; Carretero O; Lora D; Hernández-Jiménez P; Ruiz-Ruigómez M; Rodríguez-Goncer I; Silva JT; López-Medrano F; Lizasoain M; Villa J; Caro-Teller JM; Aguado JM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106517. PubMed ID: 34990760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.